Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is a biotechnology company with a strong focus on research and development. The company leverages its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs that target viral infections and liver diseases. Based in Watertown, Massachusetts, Enanta is at the forefront of developing novel inhibitors aimed at combating the hepatitis C virus (HCV), among other conditions.
Enanta's portfolio includes several classes of direct-acting antiviral (DAA) inhibitors, such as protease inhibitors, NS5A inhibitors, and nucleotide polymerase inhibitors. These are complemented by a host-targeted antiviral (HTA) inhibitor class specifically designed against cyclophilin. One of the company's most notable achievements is the development of paritaprevir, a lead protease inhibitor that is a key component of AbbVie's approved HCV treatment regimen.
In addition to HCV, Enanta is actively pursuing treatments for other serious conditions. The company has a preclinical program targeting non-alcoholic steatohepatitis (NASH), a liver disease characterized by inflammation and damage due to fat buildup. Enanta's research also extends to hepatitis B and the respiratory syncytial virus (RSV), broadening its impact on viral and liver diseases.
Enanta operates in partnership with AbbVie, which markets its protease inhibitors, while other promising drug candidates are progressing through the development pipeline. The company's commitment to innovation and strategic collaboration positions it as a significant player in the biotech industry.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced the nomination of EDP-235, an oral protease inhibitor aimed at treating COVID-19. Set to advance into clinical trials early next year, EDP-235 targets conserved regions in the virus's active site, making it resistant to mutations affecting the spike protein. Promising preclinical data show EDP-235 effectively inhibits SARS-CoV-2 replication with an EC90 of 33nM and exhibits a favorable safety profile. The company plans to apply for Fast Track designation and initiate a Phase 1 study involving about 75 healthy volunteers.
Enanta Pharmaceuticals (NASDAQ:ENTA) will release its fiscal Q3 2021 financial results on August 5, 2021, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss the financial results and updates on the company's R&D pipeline, which includes candidates for RSV, HBV, and NASH. Their funding comes from royalties associated with hepatitis C treatments developed in collaboration with AbbVie.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced the retirement of Nathalie Adda, M.D., Senior Vice President and Chief Medical Officer, effective February 2022, after which she will remain a consultant. Dr. Adda has been instrumental in overseeing Enanta's Clinical and Regulatory Department, contributing to the development of a pipeline of four clinical candidates targeting respiratory syncytial virus, hepatitis B virus, and non-alcoholic steatohepatitis. Enanta is now searching for her successor as it continues to advance its clinical programs.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced promising preclinical data for EDP-721, a novel oral therapy targeting hepatitis B virus (HBV). This data shows a significant reduction in HBV surface antigen levels by up to 3 logs in AAV-HBV mouse models. The research highlights EDP-721's potential as part of an all-oral regimen for HBV treatment and exhibits synergistic effects with other antiviral therapies. Phase 1 trials are expected to begin in mid-2021, with EDP-721 aimed at overcoming the limitations of existing HBV therapies.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported positive results from its Phase 1b study of EDP-514 in HBV patients. The study showed that EDP-514 is safe and well-tolerated, with significant mean reductions in HBV DNA of 2.9 logs and 3.3 logs for the 200 mg and 400 mg doses, respectively, after 28 days. Notably, 4 patients had HBV DNA below quantitation levels. The trial suggests EDP-514 could effectively support an all-oral treatment regimen for chronic HBV, combined with other therapies. Final results are anticipated at a future scientific conference.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced participation in two virtual investor conferences in June 2021. Jay R. Luly, Ph.D., President and CEO, will engage in a fireside chat at the JMP Securities Life Sciences Conference on June 17 at 10:30 a.m. ET and present at the Raymond James Human Health Innovation Conference on June 21 at 10:40 a.m. ET. Webcasts will be accessible on Enanta's 'Events and Presentations' page, and replays will be archived for 30 days. The company focuses on small molecule drugs for viral infections and liver diseases.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced a poster presentation of preclinical data for EDP-721, a novel oral HBV RNA destabilizer, at the EASL International Liver Congress 2021, scheduled for June 23-26, 2021. The presentation, titled 'Discovery and characterization of EDP-721,' will be led by Michael Vaine, Ph.D., and focuses on the potential of EDP-721 for an all-oral functional cure of hepatitis B virus. The company is also engaged in developing treatments for respiratory syncytial virus and other liver diseases.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced on May 18, 2021, that CEO Jay R. Luly, Ph.D., will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference at 1:20 p.m. ET. Investors can access a live webcast of the event on Enanta’s website, with a replay available for approximately 90 days afterward.
Enanta focuses on developing small molecule drugs for viral infections and liver diseases. Their clinical candidates target RSV, HBV, and NASH, with funding primarily from royalties on HCV products developed in collaboration with AbbVie.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced promising results from its Phase 1b study of EDP-514 in chronic hepatitis B virus (HBV) patients. The drug demonstrated safety and tolerability while achieving a mean reduction of HBV RNA of 1 log after 28 days, compared to 0.3 log in the placebo group. The study included 24 patients treated with nucleoside reverse transcriptase inhibitors. EDP-514 showed favorable pharmacokinetics for once-daily dosing, paving the way for combination therapies aimed at achieving functional cures for chronic HBV infection.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q2 2021 results, with total revenue of $20.1 million, down from $27.6 million year-over-year, impacted by the pandemic's effects on HCV sales. R&D expenses rose to $41.5 million from $32.6 million, while G&A expenses increased to $8.3 million. The net loss widened to $22.0 million, or $1.09 per diluted share, compared to $6.0 million, or $0.30 per share, in Q2 2020. Enanta remains well-capitalized with $400.4 million in cash, supporting its ongoing clinical programs in HBV, RSV, and NASH.
FAQ
What is the current stock price of Enanta Pharmaceuticals (ENTA)?
What is the market cap of Enanta Pharmaceuticals (ENTA)?
What is the focus of Enanta Pharmaceuticals?
Where is Enanta Pharmaceuticals located?
What are some of the diseases Enanta targets?
What is paritaprevir?
Does Enanta collaborate with other companies?
What is Enanta’s approach to drug discovery?
What is NASH?
What are DAAs?
What is an HTA inhibitor?
What makes Enanta significant in the biotech industry?
